Aspasia Gkasti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aspasia Gkasti has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alexandros Sifis
Department of Thoracic Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland
17 shared publications - Amy J. Managh
Department of Chemistry, Loughborough University, Epinal Way, Loughborough, Leicestershire, LE11 3TU, UK
17 shared publications - Christine Sempoux
Institute of Pathology, Lausanne University Hospital, 1011 Lausanne, Switzerland
17 shared publications - Damien N. Marie
Department of Thoracic Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland
17 shared publications - Daniel Clerc
Department of Visceral Surgery , 30635 Lausanne University Hospital (CHUV), University of Lausanne (UNIL) , Lausanne , Switzerland
17 shared publications - Etienne Abdelnour-Berchtold
Department of Thoracic Surgery, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland
17 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S5: Impact of HITOC on tumor-infiltrating T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S5: Impact of HITOC on tumor-infiltrating T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S6: Effect of HITOC on PD-1 and CTLA-4 expression by CD4 T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S6: Effect of HITOC on PD-1 and CTLA-4 expression by CD4 T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S1: Evaluation of the impact of heat adjunct on cisplatin cytotoxicity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S1: Evaluation of the impact of heat adjunct on cisplatin cytotoxicity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S2: Flow cytometry gating.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S2: Flow cytometry gating.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S4: Effect of HITOC on CD4 T cell infiltration in tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S4: Effect of HITOC on CD4 T cell infiltration in tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Table S2: List of antibodies used in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Table S2: List of antibodies used in the study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S3: Representative flow cytometry histograms.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S3: Representative flow cytometry histograms.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Table S1: Termination criteria used for animal experiments
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Table S1: Termination criteria used for animal experiments
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Table S1: Termination criteria used for animal experiments
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Table S1: Termination criteria used for animal experiments
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S4: Effect of HITOC on CD4 T cell infiltration in tumors.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Supplementary Figure S4: Effect of HITOC on CD4 T cell infiltration in tumors.